JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, Y.
Right arrow Articles by Wientjes, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, Y.
Right arrow Articles by Wientjes, M. G.

Vol. 299, Issue 2, 426-433, November 2001

Nontoxic Doses of Suramin Enhance Activity of Doxorubicin in Prostate Tumors

Yilong Zhang, SaeHeum Song, Fan Yang, Jessie L.-S. Au and M. Guillaume Wientjes

College of Pharmacy and James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio

We recently reported that acidic and basic fibroblast growth factors (aFGF and bFGF) confer a broad-spectrum chemoresistance in solid tumors, and that inhibitors of these proteins enhanced the antitumor activity of several anticancer drugs. The present study investigated the effect of FGF inhibitors on doxorubicin activity in human prostate PC3 tumors. In in vitro studies, conditioned medium (CM) obtained from histocultures of rat MAT-LyLu lung metastases and different combinations of recombinant FGF induced a 7- to 15-fold doxorubicin resistance. Suramin had no effect on the doxorubicin activity in the absence of CM or FGF, but reversed the CM- and FGF-induced resistance by >= 90% at concentrations that had no cytotoxicity (i.e., 1-17 µM suramin). In the in vivo study, immunodeficient mice bearing well established, subcutaneous PC3 tumors (~100 mg in size) were treated intravenously with doxorubicin (5 mg/kg) and suramin (10 mg/kg), administered twice weekly for 3 weeks. The suramin dose, selected to yield plasma concentration of below 50 µM, had neither antitumor activity nor toxicity. Doxorubicin alone reduced tumor growth rate by ~60%, reduced the density of nonapoptotic tumor cells by ~60%, enhanced the apoptotic cell fraction by 4-fold, and reduced the body weight by ~15% (p < 0.05 compared with control). Addition of suramin to doxorubicin therapy did not increase weight loss but significantly enhanced the antitumor effect, resulting in complete inhibition of tumor growth, an additional 3-fold reduction in the density of nonapoptotic tumor cells, and an additional 2-fold enhancement of the apoptotic tumor cell fraction (p < 0.05 compared with all other groups). These data indicate significant enhancement of the effectiveness of doxorubicin in prostate tumors by nontoxic and subtherapeutic doses of suramin.

0022-3565/01/2992-0426$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Ann OncolHome page
M. A. Villalona-Calero, G. A. Otterson, M. G. Wientjes, F. Weber, T. Bekaii-Saab, D. Young, A. J. Murgo, R. Jensen, T.-K. Yeh, Y. Wei, et al.
Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study
Ann. Onc., July 15, 2008; (2008) mdn412v1.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. S. Alavi, L. Acevedo, W. Min, and D. A. Cheresh
Chemoresistance of Endothelial Cells Induced by Basic Fibroblast Growth Factor Depends on Raf-1-Mediated Inhibition of the Proapoptotic Kinase, ASK1
Cancer Res., March 15, 2007; 67(6): 2766 - 2772.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. R. Horsman and D. W. Siemann
Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies
Cancer Res., December 15, 2006; 66(24): 11520 - 11539.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
B Kwabi-Addo, M Ozen, and M Ittmann
The role of fibroblast growth factors and their receptors in prostate cancer
Endocr. Relat. Cancer, December 1, 2004; 11(4): 709 - 724.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Zhao, M. G. Wientjes, and J. L-S. Au
Evaluation of Combination Chemotherapy: Integration of Nonlinear Regression, Curve Shift, Isobologram, and Combination Index Analyses
Clin. Cancer Res., December 1, 2004; 10(23): 7994 - 8004.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Song, B. Yu, Y. Wei, M. G. Wientjes, and J. L.-S. Au
Low-Dose Suramin Enhanced Paclitaxel Activity in Chemotherapy-Naive and Paclitaxel-Pretreated Human Breast Xenograft Tumors
Clin. Cancer Res., September 15, 2004; 10(18): 6058 - 6065.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. A. Villalona-Calero, M. G. Wientjes, G. A. Otterson, S. Kanter, D. Young, A. J. Murgo, B. Fischer, C. DeHoff, D. Chen, T.-K. Yeh, et al.
Phase I Study of Low-Dose Suramin as a Chemosensitizer in Patients with Advanced Non-Small Cell Lung Cancer
Clin. Cancer Res., August 1, 2003; 9(9): 3303 - 3311.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.